journal article·2019-01-09

Zingerone Nanotetramer Strengthened the Polypharmacological Efficacy of Zingerone on Human Hepatoma Cell Lines

Mei-Lang Kung, Pei-Ying Lin, Shih-Tsung Huang, Ming-Hong Tai, Shu-Ling Hsieh, Chih-Chung Wu, Bi-Wen Yeh, Wen-Jeng Wu, Shuchen Hsieh

Publisher page

Abstract

We base this study on the concept of drug repositioning to reconstitute the natural product of zingerone as zingerone nanoparticles (zingerone NPs) through a one-pot synthesized process. The as-fabricated zingerone NPs were characterized; they possessed a particle size of 1.42 ± 0.67 nm and a reconstituted structure of zingerone nanotetramer. We further validate the effects of zingerone NPs on the antitumor activity and investigate the relative underlying mechanisms on the human hepatoma SK-Hep-1 and Huh7 cell lines. Our results demonstrated that zingerone NPs significantly inhibit Akt activity and NFκB expression as well as activate the caspases cascade signaling pathway which are involved in the antiproliferation, antitumorigenicity, disturbing cell cycle progression, and induction of DNA damage as well as cell apoptosis. These findings were promising to provide a "Nano-chemoprevention" strategy in future cancer therapeutics and medical and clinical applications.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Ginger and Zingiberaceae research · Curcumin's Biomedical Applications · Piperaceae Chemical and Biological Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Doctoral Degree Program in Marine Biotechnology, Academia Sinica, Taipei 11529, Taiwan

Department of Seafood Science, National Kaohsiung University of Science and Technology, Kaohsiung 81157, Taiwan

Department of Food and Nutrition, Providence University, Taichung 43301, Taiwan

Funding

Ministry of Science and Technology, Taiwan

References (56)

Show source-provided references
1. 10.1016/j.addr.2016.04.02510.1016/j.addr.2016.04.025 ↗
2. 10.1016/j.addr.2013.09.01910.1016/j.addr.2013.09.019 ↗
3. 10.1002/jsfa.259810.1002/jsfa.2598 ↗
4. 10.1208/aapsj08022810.1208/aapsj080228 ↗
5. Sporn M. B. · Cancer Res. · 1976 · 36 · 2699
6. 10.3322/canjclin.54.3.15010.3322/canjclin.54.3.150 ↗
7. 10.2147/ijn.s9216210.2147/ijn.s92162 ↗
8. 10.2174/13894500677605491510.2174/138945006776054915 ↗
9. 10.21101/cejph.a388610.21101/cejph.a3886 ↗
10. 10.1155/2013/16275010.1155/2013/162750 ↗
11. 10.1002/anie.20110772410.1002/anie.201107724 ↗
12. 10.2174/138161281131911000410.2174/1381612811319110004 ↗
13. 10.1016/j.fct.2006.11.00210.1016/j.fct.2006.11.002 ↗
14. 10.1016/j.arabjc.2017.05.01110.1016/j.arabjc.2017.05.011 ↗
15. 10.1186/1749-8546-6-2710.1186/1749-8546-6-27 ↗
16. 10.1016/j.soncn.2005.04.00610.1016/j.soncn.2005.04.006 ↗
17. 10.1016/j.phrs.2009.01.01710.1016/j.phrs.2009.01.017 ↗
18. 10.1016/j.drudis.2010.02.00910.1016/j.drudis.2010.02.009 ↗
19. 10.1039/c4cs00269e10.1039/c4cs00269e ↗
20. 10.1080/21691401.2017.139534410.1080/21691401.2017.1395344 ↗
21. 10.1016/s1872-2040(16)60990-810.1016/s1872-2040(16)60990-8 ↗
22. 10.1038/srep0170310.1038/srep01703 ↗
23. 10.1007/s12274-014-0479-y10.1007/s12274-014-0479-y ↗
24. 10.1021/sc500242k10.1021/sc500242k ↗
25. 10.1016/j.jbiotec.2014.08.04310.1016/j.jbiotec.2014.08.043 ↗
26. 10.1155/2015/81636410.1155/2015/816364 ↗
27. 10.1021/nn300760g10.1021/nn300760g ↗
28. 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.013 ↗
29. 10.7453/gahmj.2013.00910.7453/gahmj.2013.009 ↗
30. 10.1038/nmat244210.1038/nmat2442 ↗
31. 10.4161/cib.2793410.4161/cib.27934 ↗
32. 10.1016/j.ejcb.2015.06.01010.1016/j.ejcb.2015.06.010 ↗
33. 10.1038/s41598-017-07494-010.1038/s41598-017-07494-0 ↗
34. 10.1016/j.pharmthera.2013.12.00410.1016/j.pharmthera.2013.12.004 ↗
35. 10.1038/nature0487010.1038/nature04870 ↗
36. 10.1158/1078-0432.ccr-08-012510.1158/1078-0432.ccr-08-0125 ↗
37. 10.1038/nrc78010.1038/nrc780 ↗
38. 10.1016/j.ccr.2005.08.00810.1016/j.ccr.2005.08.008 ↗
39. 10.4161/cc.2.4.43310.4161/cc.2.4.433 ↗
40. 10.1042/bst2013015610.1042/bst20130156 ↗
41. 10.1186/1747-1028-7-2610.1186/1747-1028-7-26 ↗
42. 10.1242/jcs.00953010.1242/jcs.009530 ↗
43. 10.1038/sj.emboj.760189910.1038/sj.emboj.7601899 ↗
44. Liu J. L. · Int. J. Oncol. · 2011 · 39 · 915
45. 10.1016/j.dnarep.2004.03.02410.1016/j.dnarep.2004.03.024 ↗
46. 10.1016/j.mrgentox.2005.12.00410.1016/j.mrgentox.2005.12.004 ↗
47. 10.1038/ncb88410.1038/ncb884 ↗
48. 10.4161/cc.2.5.50910.4161/cc.2.5.509 ↗
49. 10.1038/cddiscovery.2016.1110.1038/cddiscovery.2016.11 ↗
50. 10.1016/j.molcel.2006.05.02310.1016/j.molcel.2006.05.023 ↗
51. 10.1073/pnas.100217510710.1073/pnas.1002175107 ↗
52. 10.1111/j.1742-4658.2010.07975.x10.1111/j.1742-4658.2010.07975.x ↗
53. 10.1038/nrm215310.1038/nrm2153 ↗
54. 10.1038/nrm149610.1038/nrm1496 ↗
55. 10.1186/1477-7827-7-14310.1186/1477-7827-7-143 ↗
56. 10.1124/mol.105.01540410.1124/mol.105.015404 ↗